98326-32-0

98326-32-0 structure

Name	3-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydro-1H-pyridazin-6-one
Synonyms	Senazodan 6-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydropyridazin-3(2h)-one 3(2H)-Pyridazinone,4,5-dihydro-6-(4-(4-pyridinylamino)phenyl) 6-(4-(4-Pyridinylamino)phenyl)-4,5-dihydro-3(2H)-pyridazinone UNII-427L2I2KIM

Description	Senazodan is a Ca2+ sensitiser, and also shows inhibition effect on PDE III.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Research Areas >> Cardiovascular Disease
In Vitro	Senazodan seems to affect directly the actin-myosin crossbridge kinetics, and increase myosin ATPase activity[1]. Senazodan produces a concentration-dependent increase in tension development. Senazodan enhance Ca2+ binding to myofilaments and to purified cardiac troponin C. Senazodan also enhances contractility in guinea-pig papillary muscles by inhibiting PDE III[2].
References	[1]. Lehtonen LA, et al. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43(3):187-203. [2]. Erhardt L. An emerging role for calcium sensitisation in the treatment of heart failure. Expert Opin Investig Drugs. 2005 Jun;14(6):659-70.